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Preface
Armed with a vast amount of knowledge acquired at school, along with a degree in chemistry, you are starting your career in the pharmaceutical industry. You may be working in medicinal chemistry, process chemistry, or radiochemistry. This new endeavor may seem daunting, especially when you consider that you may need to be proficient in areas in which you have not been prepared. This manuscript will illustrate how chemistry, biology, pharmacokinetics, and a host of other disciplines all come together to produce successful new medicines. In order to achieve that goal, we have compiled a collection of fourteen representative categories of drugs that we have carefully chosen from among the best-selling drugs. We have provided an introduction to each drug including a historical perspective, and background to the biology, pharmacology, pharmacokinetics, and drug metabolism followed by a detailed account of the synthesis. The targeted audience goes beyond individuals new to the pharmaceutical industry; many veterans of the industry may well find something new in this text. There are a few points we felt worth reiterating. For example: a). The advent of new synthetic methodology enables chemists to synthesize drugs in a more convergent and more efficient fashion, a theme seen over and over again in this monograph. Consequently, literature awareness is essential for the chemist in the pharmaceutical industry. b). Knowing the history of successful drugs and understanding their attributes is very important and the lessons learned can be applied to current programs in drug discovery. A tremendous amount of knowledge has accumulated over the last few decades. Attributes of a successful drug include appropriate potency, selectivity, bioavailability, and physiochemical properties. c). Serendipity in the drug industry also plays an important role. On the other hand, opportunity favors prepared minds. Many examples can be found in this manuscript. For example, Viagra', currently used for erectile dysfunction (ED), was initially developed as a PDE5 inhibitor for hypertension. Likewise, Rogaine', currently used topically for hair growth, was first synthesized as a potassium channel opener, also for hypertension. Propecia@, currently used orally for hair growth, was originally VI prepared as a testosterone-5a-reductase inhibitor for the treatment of benign prostatic hyperplasia (BPH). Therefore, one should be cognizant during the clinical trials; even failure for the initially intended therapeutic indication does not necessarily equate the end of a drug as long as it has been proven to be safe. d). Another point that medicinal chemists often overlook (sometimes justifiably)
is that the synthesis of the drug should be eventually amenable to cost-effective scale-up to make it economically viable. This is where process chemists play an important role.
In the subsequent chapters, we have incorporated process synthesis routes when the information was available.
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We are also indebted to Dr. Alan J. Kraker Interestingly, only the enantiomencally pure (+)-clopidogre1 (2) exhibits platelet aggregation inhibiting activity, while the (-)-(2) is inactive." Moreover, the inactive (-)-(2) isomer is 40 times less well tolerated between the two enantiomers. Therefore, it is evidently advantageous to administer (+)-clopidogre1 (2). With regard to the enantiomencally pure (+)-clopidogre1 (2), it was originally obtained from resolution of the racemic clopidogrel (2) or through intermediates that were derived via resolution.
For in~tance,'~ racemic clopidogrel (2) was treated with levorotary camphor-10-sulfonic acid in acetone to afford a salt 19, which was recrystallized from acetone to generate (+)-clopidogrel (2). Another Sanofi synthesis of enantiomerically pure (+)-clopidogre1 (2) took advantage of resolution of racemic a-amino acid 23 to access (s)-23.I9 The methyl ester 24 was prepared by treatment of (S)-23 with thionyl chlonde and methanol. Subsequent SN2 displacement of (2-thieny1)-ethyl para-toluene-sulfonate (25) assembled m i n e 26.
